DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for ...

Do not receive XIAFLEX® if you have had an allergic reaction to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX ®, or to any other collagenase product. Please note that, ...

MALVERN, Pa., Nov. 20, 2024 /CNW/ -- Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that John Elway will share an update about his Dupuytren's contracture patient journey, including his treatment ...

DUBLIN, June 5, 2023 /PRNewswire/ -- Endo International plc (ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH, injection ...

Endo is ramping up the next phase of its Dupuytren's contracture marketing drive. Not long after running its first branded ad for Xiaflex in the indication, the drugmaker has dubbed September the ...

In a large, head-to-head trial pitting collagenase injections against limited fasciotomy as treatments for Dupuytren's contracture, the knife won. In the open-label trial, self-reported hand health ...

MALVERN, Pa., Feb. 17, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of its new branded television commercial, Steve's Journey. The campaign, featuring a real Dupuytren's ...

Campaign builds on the momentum of Endo's disease awareness efforts. Commercial features a real patient—who was an untreated patient in a prior Endo video series—and his wife, sharing their personal ...